β-Spaglumic acid  (Synonyms: β-NAAG; β-N-Acetylaspartylglutamic acid)

β-Spaglumic acid (β-NAAG) is a competitive NAAG peptidase inhibitor (K_i=1 µM) that protects spinal cord neurons from excitotoxicity and hypoxic damage. β-Spaglumic acid is also a selective mGluR3 antagonist (mGluR3 receptor functions to regulate activity-dependent synaptic potentiation in the hippocampus). β-Spaglumic acid can be used in neuroprotection-related studies^[1][2].

NAAG peptidase, mGluR3^[1][2].

β-Spaglumic acid (63-1000 µM; 2 h) protects against NMDA-induced injury of spinal cord cells in a dose-dependent manner^[1].
β-Spaglumic acid (0-1000 µM; 2 h) protects spinal cord cells against hypoxia^[1].
β-Spaglumic acid (500 µM) significantly reduces intraneuronal free Ca²⁺ responses upon neuronal exposure to 25 µM NMDA^[1].
β-Spaglumic acid (100 µM; 7 min) antagonizes mGluR3 in cerebellar granule cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

304.25

C₁₁H₁₆N₂O₈

4910-46-7

O=C(O)CC[C@@H](C(O)=O)NC(C[C@@H](C(O)=O)NC(C)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yourick DL, et al. N-acetylaspartylglutamate and beta-NAAG protect against injury induced by NMDA and hypoxia in primary spinal cord cultures. Brain Res. 2003 Nov 21;991(1-2):56-64.  [Content Brief]

  [2]. Wroblewska B, et al. β-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. J Neurophysiol. 2001 Mar;85(3):1097-106.  [Content Brief]